Castle Rock-based Triii Therapeutics is restructuring as a Texas C corporation, adding an affiliate management partner and moving 11 new supplements into production, expanding beyond its flagship Trilogiii line in 2027.
CASTLE ROCK, Colo., Nov. 16, 2026 /PRNewswire-PRWeb/ -- Triii TherapeuticsTM Announces Significant Business Milestones and Decisions
2Hill Enterprises, LCC (dba Triii TherapeuticsTM) is pleased to announce the following business milestones and decisions:
- Human Study: The human study for Triii's flagship product TrilogiiiTM (originally released in July, 2025) has been published.
- Restructuring / Re-domestication: Triii is in the process of converting from a Colorado Limited Liability Company to a Texas C-Corp and officially changing its name to Triii Therapeutics.
- Affiliate Partner Company: Triii is partnering with an affiliate management company (name to be announced separately soon), that aligns well with the company's values, to more effectively recruit and manage influencers and affiliates for the Triii brands.
- New Product Releases: Triii has made the decision to put its other products into immediate production, including the following, expected in the first half of 2027:
- TriantiiiTM Cellular Support
- TrinitiiiTM Detoxification Support
- TrigevitiiiTM Healthspan Support
- TrinergiiiTM Mitochondria / Energy Support
- TrimagiiiTM Biblical Health
- TriluciiiTM – Sleep Support
- TricardiiiTM – Cardiac Support
- TrimunitiiiTM – Immune Support
- TrirespiiiTM – Respitory Support
- TrioptiiiTM – Vision Support
- TricogniiiTM – Brain Support
- TriquilitiiiTM – Mood Support
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
About Triii Therapeutics
Triii Therapeutics is a Castle Rock, Colorado-based dietary supplement company, founded by Paul R. Myhill. The company focuses on Intelligently Designed Three-Phase Health SolutionsTM that work with the body's natural three-in-one or three-fold biological systems. Triii donates 3.33% of top-line revenues for orphaned, abandoned, trafficked, and enslaved children.
About Paul R. Myhill, Triii founder
Paul R. Myhill is a named inventor on seven U.S. patents and multiple international patents, with almost 25 years of work in nutraceuticals, primarily nutrigenomics and epigenetics. Companies he founded have generated more than $3 billion in cumulative revenue, and his formulations have been featured in nearly 50 peer-reviewed studies. Earlier in his career, he consulted for clinical dietary programs at major U.S. research hospitals.
Media Contact
Dunnie Norman, Triii Therapeutics, 1 303-731-3777, [email protected], https://triii.life/
SOURCE Triii Therapeutics

Share this article